Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 12 art units • 23 examiners • 0 of 23 (0%) have an AI response strategy ready • 68 patents granted in the last 365 days
NantWorks LLC currently has 23 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 12 distinct art units, showing that the company's research spans several different specialized biological and chemical fields. Remarkably, there are 23 distinct examiners assigned to these 23 cases, meaning that every single pending action is being reviewed by a unique individual.
GODDARD, LAURA B is listed as the busiest examiner, although they are only handling 1 pending office action. In a portfolio of 23 total actions, the fact that no examiner handles more than one case highlights a complete lack of examiner concentration. This means that the company's legal strategy must be prepared for 23 different sets of examiner preferences and interpretations across the 12 art units.
The presence of 12 distinct art units for 23 pending office actions suggests a multi-faceted approach to Biotechnology & Pharmaceuticals. Because every action is assigned to a different examiner, the company faces a broad spectrum of potential feedback with no overlap in examiner relationships. Managing these 23 actions requires a highly individualized strategy for each case, as there are no opportunities to leverage a relationship with a single examiner across multiple pending matters.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (13%) |
| §101 + other | 4 (17%) |
| §103 only | 7 (30%) |
| §112 only | 1 (4%) |
| Double-patenting only | 2 (9%) |
| Double-patenting + other | 2 (9%) |
| Multi-statute (no §101) | 4 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| ROSARIO, DENNIS | 1 | 68.7% | +29.4% |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 12.0% | +41.3% |
| SCHAETZLE, KENNEDY | 1 | 83.8% | +8.1% |
| DAGNEW, SABA | 1 | 37.5% | +17.6% |
| JOHNSON, CARLTON | 1 | 58.0% | +33.0% |
| PROSSER, ALISSA J | 1 | 15.7% | +11.2% |
| LIU, GORDON G | 1 | 82.9% | +14.8% |
| SHAH, UTPAL D | 1 | 87.9% | +11.3% |
| FENSTERMACHER, JASON B | 1 | 46.9% | +38.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | — |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17964015 | DISTRIBUTED RELATIONSHIP REASONING ENGINE FOR GENERATING ANALYTICS FOR HEMODYNAMIC INSTABILITY | HUYNH, EMILY | 41d |
| 18023190 | Computerized Tool For Prediction of Proteasomal Cleavage | ANDERSON-FEARS, KEENAN NEIL | — |
| 17376955 | Waveform Analysis And Detection Using Machine Learning Transformer Models | SCHAETZLE, KENNEDY | — |
| 19300955 | TRANSMEDIA STORY MANAGEMENT SYSTEMS AND METHODS | DAGNEW, SABA | — |
| 19004856 | COSMETIC COMPOSITIONS INCLUDING CALCIUM CARBONATE PARTICLES AND GRAPHENE | PROSSER, ALISSA J | — |
| 18677737 | HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN, SYSTEMS AND METHODS | FENSTERMACHER, JASON B | — |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | ATKINSON, JOSHUA ALEXANDER | — |
| 18185105 | VALIDATION OF INFERRED ANTICANCER PATHWAYS | LIN, JERRY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18585935 | Systems And Methods For Performing Segmentation Based On Tensor Inputs | ROSARIO, DENNIS | 7d |
| 19454185 | haNK Cetuximab Combinations And Methods | GODDARD, LAURA B | — |
| 18023190 | Computerized Tool For Prediction of Proteasomal Cleavage | ANDERSON-FEARS, KEENAN NEIL | — |
| 19300955 | TRANSMEDIA STORY MANAGEMENT SYSTEMS AND METHODS | DAGNEW, SABA | — |
| 19023205 | ENHANCED ACCESS TO MEDIA, SYSTEMS AND METHODS | JOHNSON, CARLTON | — |
| 19004856 | COSMETIC COMPOSITIONS INCLUDING CALCIUM CARBONATE PARTICLES AND GRAPHENE | PROSSER, ALISSA J | — |
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | — |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 2676 | 1 |
| 3796 | 1 |
| 2436 | 1 |
| 1619 | 1 |
| 2618 | 1 |
| 3698 | 1 |
| 1612 | 1 |
| 3683 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19454185 | haNK Cetuximab Combinations And Methods | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Jan 20, 2026 |
| 18585935 | Systems And Methods For Performing Segmentation Based On Tensor Inputs | ROSARIO, DENNIS | 2676 | §103 | Final Rejection | 7d | Pending | Feb 23, 2024 |
| 18023190 | Computerized Tool For Prediction of Proteasomal Cleavage | ANDERSON-FEARS, KEENAN NEIL | — | §101§102§103 | Non-Final OA | — | Pending | Feb 24, 2023 |
| 17376955 | Waveform Analysis And Detection Using Machine Learning Transformer Models | SCHAETZLE, KENNEDY | 3796 | §101 | Final Rejection | — | Pending | Jul 15, 2021 |
| 19300955 | TRANSMEDIA STORY MANAGEMENT SYSTEMS AND METHODS | DAGNEW, SABA | — | §101Other | Non-Final OA | — | Pending | Aug 15, 2025 |
| 19023205 | ENHANCED ACCESS TO MEDIA, SYSTEMS AND METHODS | JOHNSON, CARLTON | 2436 | §103 | Non-Final OA | — | Pending | Jan 15, 2025 |
| 19004856 | COSMETIC COMPOSITIONS INCLUDING CALCIUM CARBONATE PARTICLES AND GRAPHENE | PROSSER, ALISSA J | 1619 | §103§112 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | 2618 | §103 | Final Rejection | — | Pending | Oct 23, 2024 |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | — | DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18677737 | HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN, SYSTEMS AND METHODS | FENSTERMACHER, JASON B | 3698 | §103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | ATKINSON, JOSHUA ALEXANDER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18185105 | VALIDATION OF INFERRED ANTICANCER PATHWAYS | LIN, JERRY | — | §102§103 | Non-Final OA | — | Pending | Mar 16, 2023 |
| 17964015 | DISTRIBUTED RELATIONSHIP REASONING ENGINE FOR GENERATING ANALYTICS FOR HEMODYNAMIC INSTABILITY | HUYNH, EMILY | 3683 | §101 | Non-Final OA | 41d | Pending | Oct 11, 2022 |
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112DP | Non-Final OA | — | Pending | May 09, 2022 |
| 17236957 | VIRTUAL TELLER SYSTEMS AND METHODS | MAIDO, MAGGIE T | 2129 | §103 | Final Rejection | 19d | Pending | Apr 21, 2021 |
| 16477505 | VALIDATION OF NEOEPITOPE-BASED TREATMENT | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DPOther | Non-Final OA | — | Pending | Jul 11, 2019 |
| 18671662 | Primary T-Cell Expansion | BELYAVSKYI, MICHAIL A | — | §103 | Non-Final OA | — | Pending | May 22, 2024 |
| 18658913 | Reprogrammed T Cell-Like NK Cells | BURKHART, MICHAEL D | — | §102§103 | Non-Final OA | — | Pending | May 08, 2024 |
| 18643905 | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment | WOOLWINE, SAMUEL C | — | §103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 17932633 | Modified EC7 Cells Having Low Toxicity to Viral Production Payloads | MARVICH, MARIA | — | §112 | Non-Final OA | — | Pending | Sep 15, 2022 |
| 16961026 | Fusion Protein Extensions | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 5d | Pending | Oct 15, 2020 |
| 18522074 | Systems And Methods For Genetic Analysis Of Metastases | SULLIVAN, DENNIS JOHN | — | §101§112DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18474797 | Cancer Score for Assessment and Response Prediction from Biological Fluids | LIU, GUOZHEN | — | §101§103§112Other | Non-Final OA | — | Pending | Sep 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial